An exploration of how targeted nanoparticles and artificial intelligence algorithms combine to locate prostate cancer earlier ...
Prostate cancer remains one of the most common diseases among men, yet current screening methods often lead to unnecessary ...
TOBY’s urine-based MCED test received FDA Breakthrough Device Designation. This is the first urine-based MCED platform ...
PanGIA Biotech, Inc. ("PanGIA Biotech" or "Company") announced that two research abstracts have been accepted for ...
A recent study published in Cell Reports Medicine has identified distinct microbial signatures within the oral cavity and gut ...
Dr Oliver Hulson discusses an advanced AI software system being piloted in Leeds to help improve prostate cancer diagnosis ...
The United States Food and Drug Administration (FDA) issued guidance on its “Breakthrough Devices Program” in 2023. The ...
Is artificial intelligence the future of skin cancer detection? AI-driven healthcare data analysis identifies high-risk ...
New cfDNA test enables multicancer detection with high accuracy, offering a cost effective approach for early diagnosis and ...
TOBY, Inc., a biotechnology company developing non-invasive cancer screening technologies, today announced that the U.S. Food ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results